The HTA Council extends the stakeholder consultation period for the 2024 Provisional List of Priority HTA Topics to 10 May 2024. See the full advisory here: tinyurl.com/3k7vywn2 Only appeals that are based on the acceptable grounds, have complete sets of requirements, and submitted on time to the correct email address (htanominations@dost.gov.ph) will be processed. ————————————————————————– continue reading : EXTENSION OF THE STAKEHOLDER APPEALS PERIOD FOR THE 2024 PROVISIONAL LIST OF PRIORITY HTA TOPICS
[Advisory] Release of the Provisional TP List (April 2024)
The HTA Council hereby makes public the 2024 Provisional List of Priority HTA Topics for stakeholder consultation from 12 to 26 April 2024. Only appeals that are based on the acceptable grounds, have complete sets of requirements, and submitted on time to the correct email address will be processed. Full list of topics and important continue reading : [Advisory] Release of the Provisional TP List (April 2024)
[Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation
The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the government financing of apixaban, dabigatran, and rivaroxaban for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroups of NVAF patients through its inclusion in the Philippine National Formulary.Appeals will be accepted from continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation
[Announcement] HTA Council Releases Its Preliminary Recommendation on the Non-Financing of Cerebrolysin for Post Ischemic Stroke
The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the non-government financing of cerebrolysin in combination with rehabilitation or standard of care for the treatment of adults post-ischemic stroke through its non-inclusion in the Philippine National Formulary.Appeals will be accepted from 17 March 2023 to 31 March 2023 Kindly see full advisory:CALL FOR continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Non-Financing of Cerebrolysin for Post Ischemic Stroke
HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
(Updated as of 14 March 2023) On 24 January 2023, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of recombinant Human Erythropoietin (epoetin alfa) 4000 IU/mL solution for injection (IV/SC), 1mL pre-filled syringe, for the management of chemotherapy-induced anemia in patients with non-myeloid disease through its minor inclusion continue reading : HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe